A team of investigators report on the findings from a randomized controlled trial of 3 enhanced influenza vaccines and a standard-dose vaccine in older adults.
The FDA has approved an expanded indication for Gardasil 9® (human papillomavirus 9-valent vaccine [HPV], recombinant; Merck) to include the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58 in patients aged 9 to 45 years.
A large clinical trial of the first US COVID-19 vaccine could begin next month, according to Moderna Inc., which developed the vaccine with the US National Institutes of Health.
The purpose of this project is to implement and evaluate the effectiveness of the 4 Pillars Practice Transformation Program to increase uptake of the HPV vaccine among pediatric patients.
School-based health centers minimized the number of students excluded from school from under-immunization.
A recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine is safe, tolerable, and immunogenic.
The FDA has granted Fast Track designation to the vaccine candidate, mRNA-1273 (Moderna), against the novel coronavirus (SARS-CoV-2).
The AAP has issued a statement regarding recent data published by the Centers for Disease Control and Prevention (CDC) about a decline in pediatric vaccination during the COVID-19 pandemic.
Targeting the elderly (individuals aged 65 years) for influenza vaccination may not decrease hospitalization or mortality rates in this population.
The FDA has approved MenQuadfiTM Meningococcal (Groups A, C, Y, W; Sanofi Pasteur) Conjugate Vaccine for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in patients aged ≥2 years.
The adjuvanted, broad-spectrum influenza vaccine FLU-v was found to be immunogenic and merits phase 3 development to explore efficacy.
Microneedle array delivery of trimeric coronavirus spike protein subunit vaccines seems promising for immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
With increasing numbers of countries implementing the use of the rotavirus vaccine, rotavirus and acute gastroenteritis hospitalizations and mortalities continue to show a sustained reduction.
Currently, there are no antivirals licensed by the FDA to treat patients with COVID-19.
Implementation of an influenza immunization program increased vaccinations rates from 44% to 57% the following year.
Despite the higher effectiveness of the quadrivalent inactivated influenza vaccine against the added B virus lineage, trivalent inactivated influenza vaccine.
No significant decrease seen in incidence rates of tetanus, diphtheria with routine vaccination of adults.
The overall vaccine effectiveness against any influenza virus associated with medically attended ARI is 45% for the current season.
Updated recommendations for the use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine have been developed by the Advisory Committee on Immunization Practices (ACIP).
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has released an updated version of the child and adolescent immunization schedule for ages 18 years and younger in the United States.